Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
Nature June 1, 2024 Audrey L Warren, David Lankri, Michael J. Cunningham et al. 74 citations
Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorders1-3. These compounds are thought to mediate their hallucinogenic and therapeutic effects through the serotonin (5-hydroxytryptamine (5-HT)) receptor 5-HT2A (ref. 4). However, 5-HT1A also plays a part in the behavioural effects of tryptamine...